Theranostics and artificial intelligence: new frontiers in personalized medicine
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The field of theranostics is rapidly advancing, driven by the goals of enhancing patient care. Recent breakthroughs in artificial intelligence (AI) and its innovative theranostic applications have marked a critical step forward in nuclear medicine, leading to a significant paradigm shift in precision oncology. For instance, AI-assisted tumor characterization, including automated image interpretation, tumor segmentation, feature identification, and prediction of high-risk lesions, improves diagnostic processes, offering a precise and detailed evaluation. With a comprehensive assessment tailored to an individual's unique clinical profile, AI algorithms promise to enhance patient risk classification, thereby benefiting the alignment of patient needs with the most appropriate treatment plans. By uncovering potential factors unseeable to the human eye, such as intrinsic variations in tumor radiosensitivity or molecular profile, AI software has the potential to revolutionize the prediction of response heterogeneity. For accurate and efficient dosimetry calculations, AI technology offers significant advantages by providing customized phantoms and streamlining complex mathematical algorithms, making personalized dosimetry feasible and accessible in busy clinical settings. AI tools have the potential to be leveraged to predict and mitigate treatment-related adverse events, allowing early interventions. Additionally, generative AI can be utilized to find new targets for developing novel radiopharmaceuticals and facilitate drug discovery. However, while there is immense potential and notable interest in the role of AI in theranostics, these technologies do not lack limitations and challenges. There remains still much to be explored and understood. In this study, we investigate the current applications of AI in theranostics and seek to broaden the horizons for future research and innovation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408
Self-citationPhase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., Tagawa, S. T., Nordquist, L. T., Vaishampayan, N., El-Haddad, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107322 · Cited by 2,864 · cited 3×
“While a significant proportion of patients with high PSMA uptake show a noticeable prostate-specific antigen (PSA) response, 30% still do not achieve satisfactory PSA decline [1].”
Self-citationUnmasking Clever Hans predictors and assessing what machines really learn
Lapuschkin, S., Wäldchen, S., Binder, A., Montavon, G., Samek, W., & Müller, K.-R. (2019) · Nature Communications · doi:10.1038/s41467-019-08987-4 · Cited by 1,047
Schneider, G. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.232 · Cited by 910
Hofman, M. S., Lau, W. F. E., & Hicks, R. J. (2015) · RadioGraphics · doi:10.1148/rg.352140164 · Cited by 561
Drawbacks of artificial intelligence and their potential solutions in the healthcare sector.
khan, B., Fatima, H., Qureshi, A., Kumar, S., Hanan, A., Hussain, J., & Abdullah, S. (2023) · Biomedical Materials & Devices · doi:10.1007/s44174-023-00063-2 · Cited by 461 · cited 2×
“Also, concerns regarding the privacy and security of patient information remain paramount as AI learns from broad data collections, which may be subject to unauthorized access and misuse [80].”
Ren, F., Ding, X., Zheng, M., Korzinkin, M., Cai, X., Zhu, W., Mantsyzov, A., Aliper, A., Aladinskiy, V., Cao, Z., et al. (2023) · Chemical Science · doi:10.1039/d2sc05709c · Cited by 365 · cited 1×
“Recently, Ren et al. conducted a study demonstrating the application of AlphaFold in identifying potential drug targets [75].”
Buteau, J. P., Martin, A. J., Emmett, L., Iravani, A., Sandhu, S., Joshua, A. M., Francis, R. J., Zhang, A. Y., Scott, A. M., Lee, S.-T., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00605-2 · Cited by 296 · cited 1×
“Studies have shown that parameters such as metabolic tumor volume (MTV), an imaging-derived metric, serve as predictors for outcomes in various types of cancer treated with RNT [34-36].”
Combining structured and unstructured data for predictive models: a deep learning approach
Zhang, D., Yin, C., Zeng, J., Yuan, X., & Zhang, P. (2020) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-020-01297-6 · Cited by 269 · cited 2×
“In contrast, unstructured data, which involves formats like images or texts, lacks a predetermined organization or format, making it more complex and challenging to analyze [10].”
Cited by
Diabetes and its complications: molecular mechanisms, prevention and treatment
Zhao, L., Yuan, J., Yang, Q., Ma, J., Yang, F., Zou, Y., Liu, K., & Liu, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02401-w · Cited by 80
Lou, X., Zhou, Q., Dong, Z., Bai, L., Su, J., & Yue, H. (2025) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2025.07.010 · Cited by 17
Human-artificial intelligence symbiotic reporting for theranostic cancer care
Turner, J. H. (2025) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2024.0216 · Cited by 6
Metadata
- Authors
- Bilgin, G. B., Bilgin, C., Burkett, B. J., Orme, J. J., Childs, D. S., Thorpe, M. P., Halfdanarson, T. R., Johnson, G. B., Kendi, A. T., & Sartor, O.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2024
- Volume
- 14
- Issue
- 6
- Pages
- 2367-2378
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W4393905353
- Cited by
- 139
- References
- 11
- FWCI
- 11.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Theranostics and artificial intelligence: new frontiers in personalized medicine. https://app.cochat.ai/papers/10.7150/thno.94788
- The paper
- Bilgin, G. B., Bilgin, C., Burkett, B. J., Orme, J. J., Childs, D. S., Thorpe, M. P., Halfdanarson, T. R., Johnson, G. B., Kendi, A. T., & Sartor, O. (2024). Theranostics and artificial intelligence: new frontiers in personalized medicine. Theranostics. https://doi.org/10.7150/thno.94788
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.